Larvol Delta - Avalo-Therapeutics-Announces-First-Patient-Dosed-in-the-Phase-2-PEAK-Trial-of-AVTX002-for-the-Treatment-of-NonEosinophilic-Asthma-NEA

quisovalimab (AVTX-002) - Kyowa Kirin, Sanofi, Avalo Therap

https://www.globenewswire.com/news-release/2022/05/18/2445889/0/en/Avalo-Therapeutics-Announces-First-Patient-Dosed-in-the-Phase-2-PEAK-Trial-of-AVTX-002-for-the-Treatment-of-Non-Eosinophilic-Asthma-NEA.html

May 18, 2022

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next